This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Earns First Profit, Hep C Drug on Blockbuster Sales Pace

Updated with new information throughout.

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) reported $420 million in sales of its hepatitis C drug Incivek during the third quarter, helping the company reach profitability for the first time.

The Incivek tally for the September quarter grew almost six times over second-quarter sales of $75 million and comfortable beat Wall Street expectations which varied from $300 million to $400 million leading up to Vertex's earnings announcement.

Vertex shares closed Thursday at $42.58.

Vertex began selling Incivek in May so the accumulated $495 million in sales to date is an impressive accomplishment and distinguishes Incivek as one of the best-performing drug launches on record. Yet investors have expressed concern about independent data suggesting flattening Incivek prescription numbers over the past two months and what that means for the drug's growth and sales moving forward.

On a Thursday night call, Vertex executives revealed internal data showing Incivek sales have reached $40 million to $45 million per week in September and October. That run rate implies fourth-quarter Incivek sales in the range of $520 million to $585 million, well above the current consensus of $411 million.

Vertex officials were careful not to endorse the math or provide actual Incivek sales guidance, but the message sent was clear: Incivek's growth is far from over and investors relying on outside data services like IMS Health are not getting a complete picture of the drug's sales potential.

The same internal data, however, also seemed to validate some investor worries about Incivek because the numbers show weekly sales flat from September through October. Why? If Incivek sales remain flat or even fall, can the drug reach $2 billion in sales in 2012 -- the current analyst consensus expectation?

Vertex executives argued that Incivek's rapid, initial adoption came from the drug being used mostly by a smaller pool of doctors who tend to prescribe a relatively large percentage of drugs for hepatitis C. The next leg of growth for Incivek will come when a much larger group of doctors less familiar with the drug start to use it.

More than 70,000 hepatitis C patients have been treated with Incivek since its May 23 approval, and 60-70% of those patients are new to treatment, Vertex said. That implies Incivek still has a significant opportunity in hepatitis C patients who failed to respond to previous treatment. The number of "warehoused" patients waiting for retreatment is estimated to be between 100,000 and 300,000.

Incivek helped Vertex reach profitability for the first time. The company reported net income of $221 million, or $1.02 per share from a net loss of $209 million, or $1.04 per share, one year ago.

On an adjusted basis, Vertex earned 70 cents a share in the quarter. Total revenue was $659.2 million, up from $23.8 million in the year-ago quarter. The increase in total revenue is primarily a result of Incivek sales and $200 million in milestone revenues earned from Vertex's collaborator Johnson & Johnson (JNJ - Get Report).

Total operating expenses rose 98% in the quarter to $443.5 million from $223.4 million a year ago, including a big jump in sales and marketing expenses to $110.7 million from $48.9 million. The higher costs were largely related to the Incivek commercial launch.

Vertex CEO Matt Emmens spent a good portion of time on Thursday's call making the point that the company wants to be known for more than Incivek. A new cystic fibrosis drug, Kalydeco, has been filed for approval and could reach the market in the spring of next year. Mid-stage data from a rheumatoid arthritis pill will be presented at an upcoming medical meeting. Additional studies of the rheumatoid arthritis pill will begin early next year.

Incivek competes against Merck's (MRK - Get Report) Victrelis today but newer, potentially stronger hepatitis C drugs from Johnson & Johnson (JNJ - Get Report), Pharmasset (VRUS) and Abbott (ABT - Get Report), among others, are moving closer to approval.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $40.92 -0.99%
JNJ $95.45 -0.56%
MRK $49.47 -2.45%
VRTX $109.40 -3.40%
AAPL $111.79 0.17%


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs